These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 5484240)

  • 41. Effect of type of container, storage temperature and humidity on the biological activity of freeze-dried alkaline phosphatase.
    Ford AW; Dawson PJ
    Biologicals; 1994 Jun; 22(2):191-7. PubMed ID: 7917235
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Establishment of criteria for determining comparability of "well-characterized" proteins.
    Cavagnaro JA
    Dev Biol Stand; 1998; 96():79-81. PubMed ID: 9890519
    [No Abstract]   [Full Text] [Related]  

  • 43. [Problems raising from the control of biological products employed in medicine. Control of sera, vaccines, and biological products in France].
    Desbordes J
    Ann Ist Super Sanita; 1969; 5(3-4):218-81. PubMed ID: 16089166
    [No Abstract]   [Full Text] [Related]  

  • 44. Theoretical considerations on viral inactivation or elimination.
    Willkommen H; Löwer J
    Dev Biol Stand; 1993; 81():109-16. PubMed ID: 8174793
    [No Abstract]   [Full Text] [Related]  

  • 45. International acceptance of blood and blood products.
    Petricciani JC
    Dev Biol (Basel); 2000; 102():3-8. PubMed ID: 10794085
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Problems and progress in biological products control.
    Hejl JM
    J Am Vet Med Assoc; 1968 Dec; 153(12):1803-8. PubMed ID: 5725849
    [No Abstract]   [Full Text] [Related]  

  • 47. Investigation by bioassay of the efficacy of sodium hydroxide treatment on the inactivation of mouse-adapted scrapie.
    Unal A; Thyer J; Uren E; Middleton D; Braun M; Maher D
    Biologicals; 2007 Jun; 35(3):161-4. PubMed ID: 17074508
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [LAL (Limulus Amoebocyte Lysate) test as applied to the safety evaluation of biological preparations].
    Aleksandrowicz J; Kudelski Z
    Rocz Panstw Zakl Hig; 1997; 48(3):275-82. PubMed ID: 9432705
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Interactions between hematological derivatives and dipalmitoyl phosphatidyl choline: implications for adult respiratory distress syndrome.
    Banerjee RR
    Colloids Surf B Biointerfaces; 2004 Mar; 34(2):95-104. PubMed ID: 15261079
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Product traceability and lookback: assuring the integrity of the transfusion process.
    Flanagan P
    Dev Biol (Basel); 2007; 127():225-33. PubMed ID: 17486896
    [No Abstract]   [Full Text] [Related]  

  • 51. WHO Expert Committee on biological standardization.
    World Health Organ Tech Rep Ser; 2007; (941):1-340, back cover. PubMed ID: 18314862
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Process changes and their effect on process evaluation for viral clearance.
    Marcus-Sekura C
    Dev Biol Stand; 1996; 88():125-30. PubMed ID: 9119123
    [TBL] [Abstract][Full Text] [Related]  

  • 53. WHO activities to assure the quality of biological products.
    Magrath D
    Dev Biol Stand; 1993; 81():265-8. PubMed ID: 8174812
    [No Abstract]   [Full Text] [Related]  

  • 54. Removal of TSE agents from blood products.
    Foster PR
    Vox Sang; 2004 Jul; 87 Suppl 2():7-10. PubMed ID: 15209867
    [No Abstract]   [Full Text] [Related]  

  • 55. Recovery of an erythropoietin inducing factor from the regenerating rat liver.
    Dornfest BS; Naughton BA; Kolks GA; Liu P; Piliero SJ; Gordon AS
    Ann Clin Lab Sci; 1981; 11(1):37-46. PubMed ID: 7212628
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Additional standards for human blood and blood products, source plasma (human); amendment of storage temperature requirements: Food and Drug Administration, Final rule.
    Fed Regist; 1980 Dec; 45(236):80500-1. PubMed ID: 10249304
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Clavatadine A, a natural product with selective recognition and irreversible inhibition of factor XIa.
    Buchanan MS; Carroll AR; Wessling D; Jobling M; Avery VM; Davis RA; Feng Y; Xue Y; Oster L; Fex T; Deinum J; Hooper JN; Quinn RJ
    J Med Chem; 2008 Jun; 51(12):3583-7. PubMed ID: 18510371
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Collection of source material from remunerated donors.
    Rodell MB
    Dev Biol Stand; 1993; 81():57-64. PubMed ID: 8174821
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Definition of a well-characterized biotechnology product.
    Zoon K; Garnick R
    Dev Biol Stand; 1998; 96():191-7. PubMed ID: 9890531
    [No Abstract]   [Full Text] [Related]  

  • 60. Evaluation of the transfusion safety of blood products and determination of plasma concentrations of acitretin and etretinate in patients receiving transfusions.
    Park HD; Kim HK; Kim JW; Kim DW; Lee JH; Huh W; Youn JI; Kim HG; Kim YG; Kim MH; Lee SY
    Transfusion; 2008 Nov; 48(11):2395-400. PubMed ID: 18657077
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.